Who are Arcellx's investors?

Arcellx's investors include LG Technology Ventures, New Enterprise Associates (NEA), Quan Capital, Samsara BioCapital, Sixty Degree Capital, Solasta Ventures, SR One Capital Management, Norwest Venture Partners and 3 more.

How much funding has Arcellx raised?

Arcellx has disclosed $272.8M raised across 4 rounds.

Where is Arcellx headquartered?

Arcellx is headquartered in Gaithersburg, US.

Arcellx

Gaithersburg, US · Delaware corporation · 4,056 employees on LinkedIn · 22 known investors

Find your way into Arcellx

Paths you didn't know you had: your email and LinkedIn already hold routes to the Arcellx team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer. The company focuses on cell therapy for cancer treatment.

Biotech Healthtech

Founders & leadership

Han LeeExecutive

Rami Elghandour Chairman & Chief Executive OfficerRami Elghandour is Chairman and CEO of Arcellx, a biotechnology company developing CAR T-cell and other immunotherapies for cancer and autoimmune diseases. He previously served as President and CEO of Nevro Corporation, a medical device company, and began his career as a design engineer developing implantable neurostimulators before working as a venture capitalist at Johnson and Johnson Development Corporation; he holds an MBA from Wharton and a BS in Electrical and Computer Engineering from Rutgers University.

Board

Jill Carroll Board directorOperating Partner - Portfolio Value Creation at SR One Capital Management

Ali Behbahani Board directorPartner, Co-Head of Healthcare at New Enterprise Associates (NEA)

Derek Yoon Board directorPresident & CEO at Solasta Ventures

Tiba Aynechi Member Board of Directors2015–2021General Partner at Norwest Venture Partners

Lewis T. Rusty WilliamsBoard director

David LubnerBoard director

Investors · 22

LG Technology Ventureslisted by LG Technology VenturesSilicon Valley

How we know: LG Technology Ventures's portfolio page · the VCSheet dataset · Not right? Tell us

New Enterprise Associates (NEA)listed by New Enterprise Associates (NEA)Menlo Park · $200K – $40Mvia Kavita Patel · board

How we know: board seat on SEC Form D · globalgenes.org · open dataset · 5k.vc investor directory · Not right? Tell us

Quan Capitallisted by Quan CapitalShanghai

Samsara BioCapitallisted by Samsara BioCapitalMenlo Park

How we know: Samsara BioCapital's portfolio page · a partner's Signal profile · globalgenes.org · Not right? Tell us

Sixty Degree Capitallisted by Sixty Degree CapitalNorth York

How we know: Sixty Degree Capital's portfolio page · globalgenes.org · open dataset · 5k.vc investor directory · Not right? Tell us

Solasta Ventureslisted by Solasta VenturesBoston

How we know: open dataset · 5k.vc investor directory · Not right? Tell us

SR One Capital Managementlisted by SR One Capital ManagementRedwood City

How we know: SR One Capital Management's portfolio page · Not right? Tell us

Norwest Venture PartnersinferredMenlo Park · $10M – $30Mvia Tiba Aynechi · board

How we know: board seat on SEC Form D · Not right? Tell us

Novo HoldingsreportedCopenhagen · $1.1M – $54M

How we know: globalgenes.org · Not right? Tell us

Soleus CapitalreportedGreenwich

How we know: globalgenes.org · Not right? Tell us

Takeda VenturesreportedCambridge · $1M – $5M

How we know: globalgenes.org · Not right? Tell us

Also in the syndicate · 11

AdageAsymmetryCaaS CapitalCAM CapitalleadCambrian BioClough CapitalLG TechSR OneSurveyor Capital (a Citadel company)SuvrettaTerra Magnum Capital Partners

Reported raises · per SEC filings

Form D private placements

$272.8M disclosed across 4 rounds · 2019–2023

▶$100MraisedFeb 2023 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Derek YoonDirector
Michelle GilsonExecutive Officer
Rami ElghandourExecutive Officer, Director
Ali BehbahaniDirector
Olivia WareDirector
David LubnerDirector
Kavita PatelDirector
Christopher HeeryExecutive Officer
Jill CarrollDirector

Offering amount: $100M
Amount sold: $100M
First sale: Jan 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$10MraisedMar 2022 · 1 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Derek YoonDirector
David LubnerDirector
Lance ThibaultExecutive Officer
Ali BehbahaniDirector
Jill CarrollDirector
Rami ElghandourExecutive Officer, Director
Kavita PatelDirector
Lewis T. WilliamsDirector

Offering amount: $10M
Amount sold: $10M
First sale: Feb 2022
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$120MraisedJul 2021 · 32 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Han LeeExecutive Officer
Lewis T. Rusty WilliamsDirector
Jill CarrollDirector
David LubnerDirector
Ali BehbahaniDirector
Derek YoonDirector
Rami ElghandourExecutive Officer, Director
Tiba AynechiDirector

Offering amount: $120M
Amount sold: $120M
Finders' fees: $570K
Placement agents: Solebury Capital LLC
First sale: Mar 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$42.8MraisedOct 2019 · 18 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Ali BehbahaniDirector
Hugo BeekmanDirector
David HilbertExecutive Officer, Director
Han LeeExecutive Officer
Lewis T. Rusty WilliamsDirector
Tiba AynechiDirector
Jill CarrollDirector
Roger SawhneyDirector

Offering amount: $83.7M
Amount sold: $42.8M
First sale: Aug 2019
Incorporated: Corporation, Delaware, 2014
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 2

Kite PharmaKite develops CAR T-cell therapies that engineer a patient's own immune cells to target and destroy cancer cells. The company focuses on cell therapy treatments for cancers such as diffuse large B-cell lymphoma.

ExelixisExelixis is an oncology company that discovers and develops cancer treatments, including small molecule therapeutics and biotherapeutics such as antibody-drug conjugates, for patients across multiple tumor types. Its flagship commercial product is CABOMETYX (cabozantinib), and it operates through global development and commercialization partnerships.

Companies working in the same space as Arcellx.

Frequently asked questions

What does Arcellx do?: Arcellx develops CAR T-cell therapies that are individually designed for each patient, using the immune system to target and attack cancer. The company focuses on cell therapy for cancer treatment.
Who are Arcellx's investors?: Arcellx's investors include LG Technology Ventures, New Enterprise Associates (NEA), Quan Capital, Samsara BioCapital, Sixty Degree Capital, Solasta Ventures, SR One Capital Management, Norwest Venture Partners and 3 more.
How much funding has Arcellx raised?: Arcellx has disclosed $272.8M raised across 4 rounds.
Where is Arcellx headquartered?: Arcellx is headquartered in Gaithersburg, US.